Watchlist
FRNM · Freenome, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31 invalidates the case.
Kill line
A weekly close below $14 invalidates the post-approval price thesis; separately, no announced US commercial launch of SimpleScreen CRC by 2026-12-31 invalidates the commercial-timing case.
Pick status
Open commitment scored if the kill line above fires How this is scored →Latest analysis and events for FRNM —
As of 8 September 2026, the latest FrontierPicks analysis for Freenome, Inc. (FRNM): Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31 invalidates the case.
Kill line: A weekly close below $14 invalidates the post-approval price thesis; separately, no announced US commercial launch of SimpleScreen CRC by 2026-12-31 invalidates the commercial-timing case.
Current Thesis
Freenome's approved colorectal cancer blood test remains an Abbott distribution story: an actual US launch and disclosed reimbursed testing would establish commercial execution, while a weekly close below $14 would invalidate the price thesis. Abbott's 2026-07-27 announcement specified a fall-2026 launch of SimpleScreen CRC; Freenome's reported Q2 2026 revenue was $2.3 million. Approval announcement
The substantive update to the 2026-09-07 assessment is payer documentation. Carelon's guideline, reviewed on 2026-08-08 and effective 2026-11-15, names SimpleScreen CRC as medically necessary subject to criteria. Eligibility requires preferred screening to have been declined, unavailable to complete or not completed; plan implementation dates may differ. This supports a restricted reimbursement pathway, rather than current coverage across all plans. Carelon guideline
As an inference from the analyst initiations dated 2026-08-14 through 2026-08-20, the 2026-09-01 reimbursement headline and the market's 2026-09-03 high, the narrative is accelerating. That classification describes expanding attention; it does not establish commercial adoption. The probability assessment is modestly favorable because primary payer documentation strengthens the case, while launch execution remains unresolved.
Bullish and bearish views on Freenome, Inc.
The model's bull view on Freenome, Inc. (FRNM), in brief: Approval establishes a commercial product. The bear view: Commercial revenue remains unproven. Freenome's Q2 results dated 2026-09-01 reported $2.3 million revenue and a $69.0 million net loss. Those figures do not establish the economics of an Abbott-led launch that had been announced for fall 2026. Precancer detection limits the… Both cases follow in full.
Bull Case
- Approval establishes a commercial product. Freenome's 2026-07-27 announcement reported Food and Drug Administration approval, with 81.1% colorectal cancer sensitivity and 90.4% specificity for advanced colorectal neoplasia. These are reported diagnostic-performance measures, not evidence of sales. Approval announcement
- Distribution agreement has financial substance. The 2026-07-27 announcement identified Abbott as exclusive US commercializer and an approval-triggered $100 million milestone payment to Freenome. The contractual milestone supports the partnership's economic relevance without establishing recurring testing revenue. Approval announcement
- Analyst attention broadened in August. Benzinga reported Leerink's $18 target on 2026-08-14, Jefferies' and BTIG's $17 targets on 2026-08-17, TD Cowen's $17 target on 2026-08-18 and Guggenheim's $21 target on 2026-08-20. Those initiations document coverage expansion; they do not measure subsequent investor demand.
Bear Case
- Commercial revenue remains unproven. Freenome's Q2 results dated 2026-09-01 reported $2.3 million revenue and a $69.0 million net loss. Those figures do not establish the economics of an Abbott-led launch that had been announced for fall 2026.
- Precancer detection limits the proposition. The 2026-07-27 approval release reported 13.7% sensitivity for advanced precancerous lesions. That clinical limitation remains relevant when assessing screening adoption. Approval announcement
- Registered resale supply remains material. The 2026-08-18 prospectus covered up to 75,188,742 common shares offered by selling securityholders, according to Benzinga's filing report. Registration establishes potential supply; the supplied evidence does not establish completed sales or the timing of lock-up releases.
Setup & Price Structure
The adjusted daily series records a $16.31 close on 2026-09-04, 3.5% below the $16.90 high recorded on 2026-09-03. The supplied three-month price change was 46.3%, and the 14-day relative strength index (RSI) was 82.8. These are measured momentum observations; no moving-average value or trading-volume series was supplied.
The August analyst cluster, September reimbursement headline and elevated RSI document concentrated attention and strong recent price momentum. They do not establish crowded ownership: short interest, investor-flow data and a representative retail-sentiment sample are missing. The sample is too small to support a retail-crowding claim.
The $14 weekly-close threshold defines failure of this research thesis. It is not supported here by a measured moving average or a demonstrated historical support shelf. The $16.90 market high is an observable reference for the advance, without implying a forecast return.
Catalyst Calendar (next 30 days)
For 2026-09-08 through 2026-10-08, no confirmed company event appears on the Freenome or Abbott calendars reviewed on 2026-09-08. A precise launch date and the next earnings dates remain unconfirmed; the earlier estimated September payer checkpoint is not a scheduled event. Freenome investor calendar, Abbott event calendar
- 2026-11-15 — Payer guideline effective date. Carelon's published revision names SimpleScreen CRC; implementation varies by health plan. This later date matters directly to the reimbursement thesis. Carelon guideline
Abbott's launch remains described as fall 2026 in the 2026-07-27 announcement. No exact calendar date is established by that wording. Approval announcement
What Would Change Our Mind
Failure of the post-approval price advance would end the thesis at a weekly close below $14. Separately, no announced US launch by 2026-12-31 would invalidate the commercial-timing case. That year-end date is the research deadline, not an Abbott commitment.
The positive case would be established by an announced US launch and disclosed reimbursed SimpleScreen CRC testing before that deadline and before the price condition fires. A launch announcement alone would leave adoption unresolved. Removal of the test from Carelon's 2026-11-15 guideline would reverse the payer improvement identified in this refresh. Carelon guideline
Correlation Notes
The supplied biotechnology catalyst-group record classified the theme as accelerating on 2026-09-06, following the same classification on 2026-08-09 and 2026-08-13. That is evidence about the group's editorial classification, not measured return correlation or proof of demand for Freenome. No paired return series was supplied, so a numerical correlation claim is unsupported.
Abbott is a direct commercial dependency under the agreement described on 2026-07-27. Its launch execution matters to this thesis independently of the biotech group's classification; a stronger group cannot resolve a missed company launch deadline. Approval announcement
Notes
- Listed via SPAC merger on 2026-07-21; roughly seven weeks of trading history, so there is no multi-quarter chart structure to reference.
- transfer-price terms are undisclosed, so test volume does not translate one-for-one into Freenome revenue.
- lock-up release terms were not confirmed in public material reviewed.
- Sensitivity for advanced precancerous lesions was 13.7% (30.7% with high-grade dysplasia) per the 2026-07-27 approval release — the clinical limitation payers and guideline bodies weigh.
- Q2 2026 net loss was $69.0M against ~$102.0M cash and short-term securities at 2026-06-30 plus $295.5M net SPAC proceeds; the runway statement covers 12 months from issuance.
Related · shared themes
ABSI
Absci Corporation
Absci Corporation’s valuation rests on ABS-201 delivering human hair-growth efficacy in the guided second half of 2026. Separation from placebo would validate the case; a weekly close below $7.50, absent efficacy or a missed readout window would invalidate it.
ALVO
Alvotech
Alvotech's recovery prices in Q4 2026 FDA approvals after the Reykjavik inspection closure announced on 2026-07-29. AVT05 and AVT06 approvals within that window would confirm the regulatory-repair case; another manufacturing-related rejection would break it.
GHRS
GH Research PLC
Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next takeout. Phase 3 FDA alignment is the gate.
MANE
Veradermics, Incorporated
Veradermics’ oral minoxidil story depends on Study ‘304’ replicating the reported hair-growth benefit by year-end 2026. Failed replication, a weekly close below $85, or the reporting window expiring without results would invalidate the case.